Clinical trial
Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy
NCT00433745 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00433745 |
|---|---|
| Title | Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy |
| Official title | Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML) |
| Intervention type | Drug |
| Interventions | WT1 Peptide Vaccine |
| Enrollment | 4 |
| Start date | Feb 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2009 |
| First posted | Feb 12, 2007 |
| Last update posted | Jul 8, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: